Komori
Revision of earnings forecasts2183Linical Co.,Ltd.Information and Communications, Services and Others

Summary of Financial Results for the Fiscal Year Ending March 2026 [Japanese GAAP] (Consolidated)

In the fiscal year ended March 2026, revenue fell 17.0% year on year as the completion of large-scale projects in the US and Europe coincided with delays in the start of new projects, resulting in wider operating, ordinary and net losses. For the fiscal year ending March 2027, the company expects to return to profitability, forecasting revenue of ¥10,680 million and operating profit of ¥256 million, based on the assumption that delayed projects will resume operations.

Worth reading
82Important
Scored from 4 of 5 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
-17
Year-on-year change in revenue (%)
Wording
Avoiding a definitive answer
How definitive the wording is.

Revised forecast

Fiscal year ending March 2027 · Full year
Net Sales—→10,680million
—
Operating profit—→256million
—
Ordinary income—→250million
—
Profit attributable to owners of the parent—→180million
—
Net income per share—→7.97yen
—

The bar length represents the relative magnitude of change, based on the item that changed the most in this document.

Reason for the revision

Some projects whose starts had been delayed in the US and Europe have begun to resume operations, and the remaining projects, along with recently acquired orders, are expected to commence operations sequentially. If large-scale orders are secured and progress smoothly, both revenue and profit are expected to improve substantially in the second half, while the contribution in the first half is expected to be limited because new projects will be in the start-up phase.

Details and amount of extraordinary loss

Impairment losses of ¥989.154 million (¥159.170 million on business assets in Japan and ¥829.984 million on goodwill in Europe), and loss on disposal of fixed assets of ¥1.246 million. Total extraordinary losses: ¥990.401 million.

Previous-period resultsRevenue: ¥10,437 million; operating loss: ¥2,073 million; ordinary loss: ¥2,023 million; net loss attributable to owners of the parent: ¥3,329 million
Dividend forecast revisionThe forecast year-end dividend for the fiscal year ending March 2027 is ¥8 per share, or ¥8 for the full year. It is not explicitly stated whether the dividend forecast was revised.
Consolidated / non-consolidatedConsolidated
Revised forecast
ItemDetails
Net SalesNot disclosed → ¥10,680 million
Operating profitNot disclosed → ¥256 million
Ordinary incomeNot disclosed → ¥250 million
Profit attributable to owners of the parentNot disclosed → ¥180 million
Net income per shareNot disclosed → 7.97 yen
Fiscal Period CoveredFiscal year ending March 2027
Period CoveredFull year
Previous-period resultsRevenue: ¥10,437 million; operating loss: ¥2,073 million; ordinary loss: ¥2,023 million; net loss attributable to owners of the parent: ¥3,329 million
Reason for the revisionSome projects whose starts had been delayed in the US and Europe have begun to resume operations, and the remaining projects, along with recently acquired orders, are expected to commence operations sequentially. If large-scale orders are secured and progress smoothly, both revenue and profit are expected to improve substantially in the second half, while the contribution in the first half is expected to be limited because new projects will be in the start-up phase.
Details and amount of extraordinary lossImpairment losses of ¥989.154 million (¥159.170 million on business assets in Japan and ¥829.984 million on goodwill in Europe), and loss on disposal of fixed assets of ¥1.246 million. Total extraordinary losses: ¥990.401 million.
Dividend forecast revisionThe forecast year-end dividend for the fiscal year ending March 2027 is ¥8 per share, or ¥8 for the full year. It is not explicitly stated whether the dividend forecast was revised.
Consolidated / non-consolidatedConsolidated
Items this document does not state (1)
Publication date of previous forecast

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Although the company won large-scale new projects, delays in their start meant that the resulting revenue could not offset the decline caused by the completion of existing large-scale projects, leading to a substantial decrease in revenue in the US and Europe. In addition, the company recorded impairment losses on goodwill related to its European operations and fixed assets related to its Japanese operations, and reversed deferred tax assets.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Summary of Financial Results for the Fiscal Year Ending March 2026 [Japanese GAAP] (Consolidated) | Linical Co.,Ltd. (2183) timely disclosure | Komori